August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
October 2023 in “Frontiers in medicine” Targeted immunotherapy could be a promising new treatment for hair regrowth.
184 citations,
February 2015 in “EBioMedicine” A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
182 citations,
December 2017 in “Journal of the American Academy of Dermatology” Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.
116 citations,
February 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors help with skin conditions but need more research on dosing and safety.
77 citations,
June 2017 in “Advances in Therapy” New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
76 citations,
February 2021 in “International Journal of Molecular Sciences” Mesenchymal stem cells show potential for skin healing and anti-aging, but more research is needed for safe use, especially regarding stem cells from induced pluripotent sources.
66 citations,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
59 citations,
June 2022 in “Frontiers in medicine” There are still challenges in diagnosing and treating chronic skin diseases, but there is hope for future improvements.
53 citations,
February 2020 in “Expert Opinion on Pharmacotherapy” Finasteride and minoxidil work best together for hair loss.
51 citations,
June 2016 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.
40 citations,
August 2022 in “Frontiers in immunology” Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
37 citations,
August 2022 in “Frontiers in pharmacology” Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.
37 citations,
January 2016 in “Drug design, development and therapy” Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.
30 citations,
May 2016 in “Expert Opinion on Biological Therapy” New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.
26 citations,
January 2019 in “Expert Opinion on Investigational Drugs” New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.
25 citations,
July 2013 in “Actas Dermo-Sifiliográficas” Acitretin is effective for severe psoriasis and can be used long-term due to no immunosuppression, but must be carefully monitored for side effects and is not for pregnant women.
20 citations,
September 2020 in “Journal of Translational Medicine” Mesenchymal stromal cells may help treat severe COVID-19, but more research is needed to confirm their effectiveness.
14 citations,
January 2020 in “Mediterranean Journal of Rheumatology” New JAK inhibitor drugs show promise for treating skin diseases but need more research on safety and effectiveness.
12 citations,
June 2023 in “JAMA network open” JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.
10 citations,
January 2023 in “Acta dermato-venereologica” Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
8 citations,
February 2019 in “Journal of The European Academy of Dermatology and Venereology” 7 citations,
April 2023 in “Frontiers in immunology” Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
7 citations,
December 2019 in “American Journal of Clinical Dermatology” Topical therapies show promise for hair loss and acne treatment with minimal side effects.
4 citations,
November 2023 in “Frontiers in immunology” New treatments targeting T-cell pathways are needed for better alopecia areata management.
4 citations,
June 2023 in “Frontiers in immunology” JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.
4 citations,
September 2012 in “Clinical Pharmacology in Drug Development” Different drug doses approved in Japan and the U.S. are not mainly due to different clinical responses, and ethnic factors should be considered in setting drug doses.
3 citations,
May 2023 in “Frontiers in immunology” Faulty inflammasome activation may lead to autoimmune skin diseases and could be a target for new treatments.
3 citations,
May 2018 in “Experimental Dermatology” Young HS patients often have other physical and mental health issues, and research on HS covers a wide range of topics including genetics, triggers, treatments, and the need for more data.
1 citations,
October 2023 in “Dermatology and therapy” Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.